Supramolecular nanosubstrate-mediated delivery system enables CRISPR-Cas9 knockin of hemoglobin beta gene for hemoglobinopathies.

Supramolecular nanosubstrate-mediated delivery system enables CRISPR-Cas9 knockin of hemoglobin beta gene for hemoglobinopathies.
复制标题

DOI:
10.1126/sciadv.abb7107
复制
发表时间:
2020-10
期刊:
影响因子:
13.6
通讯作者:
Tseng HR
Tseng HR
中科院分区:
综合性期刊1区
文献类型:
--
作者:
Yang P;Chou SJ;Li J;Hui W;Liu W;Sun N;Zhang RY;Zhu Y;Tsai ML;Lai HI;Smalley M;Zhang X;Chen J;Romero Z;Liu D;Ke Z;Zou C;Lee CF;Jonas SJ;Ban Q;Weiss PS;Kohn DB;Chen K;Chiou SH;Tseng HR

文献摘要

参考文献

相似文献

CRISPR-Cas9敲击HBB基因为治疗血红蛋白疾病的一般治疗方案铺平了道路。利用内源性同源定向修复(HDR)途径,CRISPR-Cas9基因编辑系统可以应用于在基因组的指定位置敲入治疗性基因,为治疗血红蛋白病等遗传性疾病提供一种通用的治疗方案。在这里,超分子纳米颗粒(SMNP)/超分子纳米底物介导的递送(SNSMD)相结合的策略被用于促进CRISPR-Cas9将血红蛋白β(HBB)基因敲入携带镰状细胞病突变的工程K562 3.21细胞系的腺相关病毒整合位点1(AAVS1)安全港。通过对包裹了Cas9·单引导RNA(SgRNA)复合体和HBB/绿色荧光蛋白(GFP)编码质粒的两个SMNP载体的分步处理,成功地通过HDR获得了CRISPR-Cas9敲打蛋白。最后,将HBB/GFP-K562 3.21细胞通过腹腔注射导入小鼠体内,以显示其体内增殖能力。这一概念验证演示为治疗血红蛋白疾病的一般基因治疗解决方案铺平了道路。
CRISPR-Cas9 knockin of the HBB gene paves the way for a general therapeutic solution for treating hemoglobinopathies. Leveraging the endogenous homology-directed repair (HDR) pathway, the CRISPR-Cas9 gene-editing system can be applied to knock in a therapeutic gene at a designated site in the genome, offering a general therapeutic solution for treating genetic diseases such as hemoglobinopathies. Here, a combined supramolecular nanoparticle (SMNP)/supramolecular nanosubstrate–mediated delivery (SNSMD) strategy is used to facilitate CRISPR-Cas9 knockin of the hemoglobin beta (HBB) gene into the adeno-associated virus integration site 1 (AAVS1) safe-harbor site of an engineered K562 3.21 cell line harboring the sickle cell disease mutation. Through stepwise treatments of the two SMNP vectors encapsulating a Cas9•single-guide RNA (sgRNA) complex and an HBB/green fluorescent protein (GFP)–encoding plasmid, CRISPR-Cas9 knockin was successfully achieved via HDR. Last, the HBB/GFP-knockin K562 3.21 cells were introduced into mice via intraperitoneal injection to show their in vivo proliferative potential. This proof-of-concept demonstration paves the way for general gene therapeutic solutions for treating hemoglobinopathies.
通过生物可还原脂质和信使 RNA 纳米颗粒实现快速高效的体内 CRISPR/Cas9 基因组编辑
DOI: 10.1002/adma.201902575
发表时间: 2019-08-01
期刊: ADVANCED MATERIALS
影响因子: 29.4
作者:
Liu, Ji;Chang, Jin;Wang, Ming
通讯作者: Wang, Ming
DOI: 10.1002/anie.201507546
发表时间: 2016-01-04
期刊: Angewandte Chemie (International ed. in English)
影响因子: --
作者:
Liu Y;Du J;Choi JS;Chen KJ;Hou S;Yan M;Lin WY;Chen KS;Ro T;Lipshutz GS;Wu L;Shi L;Lu Y;Tseng HR;Wang H
通讯作者: Wang H
DOI: 10.1021/nn5003024
发表时间: 2014-05-27
期刊: ACS NANO
影响因子: 17.1
作者:
Peng, Jinliang;Garcia, Mitch Andre;Choi, Jin-sil;Zhao, Libo;Chen, Kuan-Ju;Bernstein, James R.;Peyda, Parham;Hsiao, Yu-Sheng;Liu, Katherine W.;Lin, Wei-Yu;Pyle, April D.;Wang, Hao;Hou, Shuang;Tseng, Hsian-Rong
通讯作者: Tseng, Hsian-Rong
DOI: 10.1038/nbt.3198
发表时间: 2015-05-01
影响因子: 46.9
作者:
Van Trung Chu;Weber, Timm;Kuehn, Ralf
通讯作者: Kuehn, Ralf
DOI: 10.1093/nar/gkw064
发表时间: 2016-05-19
影响因子: 14.9
作者:
He X;Tan C;Wang F;Wang Y;Zhou R;Cui D;You W;Zhao H;Ren J;Feng B
通讯作者: Feng B